Rani (RANI) Q2 Net Loss Improves 16%
Financial Performance: Rani Therapeutics reported no revenue for Q2 2025, with a net loss of $(11.2) million, an improvement from the previous year, but cash reserves significantly declined to $10.2 million from $27.6 million since December 2024.
Pipeline Development: The company is advancing its oral biologic drug delivery technology, with plans to initiate a Phase 1 clinical trial for its RT-114 candidate in the second half of 2025, while managing costs and securing strategic partnerships amid ongoing financial challenges.
Trade with 70% Backtested Accuracy
Analyst Views on RANI
About RANI
About the author
Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead
Tactile Systems Technology Inc. (TCMD): The company saw a 22.13% increase in after-hours trading after reporting a strong Q3 2025 earnings with net income rising to $8.2 million and revenue climbing 17% year-over-year. They also raised their full-year revenue guidance to $317 million - $321 million.
Biodesix Inc. (BDSX): Shares surged 10.57% after the company reported a 20% increase in Q3 2025 revenue to $21.8 million and a narrowed net loss. They raised their full-year revenue forecast to $84 million - $86 million, indicating sustained growth.
Exact Sciences Corp. (EXAS): The stock rose 7.78% following a Q3 2025 earnings report showing a 20% revenue increase to $851 million and a significantly narrowed net loss. The company also raised its full-year revenue guidance to $3.220 - $3.235 billion.
Rani Therapeutics (RANI) and Grace Therapeutics Inc. (GRCE): Rani's shares increased 5.12% ahead of a presentation at ObesityWeek 2025, while Grace's stock rose 6.11% following the full exercise of common warrants tied to a previous funding round, securing additional capital for their drug candidate.
Insider Buying Update for Tuesday, October 28: RANI and KO
Rani Therapeutics Holdings Insider Purchase: Mir Imran, the CEO of Rani Therapeutics Holdings, bought 2,083,334 shares of RANI for $1.26 million, resulting in a 228.9% gain based on the current trading price.
Coca-Cola Insider Purchase: Director Max R. Levchin purchased 14,267 shares of Coca-Cola for $998,676, marking his first purchase in the past year, with Coca-Cola's stock up 0.5% on the same day.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
3 Penny Stocks to Keep an Eye On as of October 22, 2025
Penny Stocks Overview: Beyond Meat, Rani Therapeutics, and VSee Health are highlighted as top penny stocks to watch on October 22, 2025, based on their high Dollar Volume and significant stock price movements.
Beyond Meat's Growth: Beyond Meat's stock surged by 146.3% with a Dollar Volume of $7.50 billion, following its expansion into over 2,000 Walmart stores to reach more budget-conscious consumers.
Rani Therapeutics' Licensing Deal: Rani Therapeutics experienced a 27% stock increase and a Dollar Volume of $355.82 million after announcing a $1.09 billion licensing deal with Chugai Pharmaceutical and a successful private placement.
VSee Health's Telehealth Contract: VSee Health's stock rose by 93.6% with a Dollar Volume of $248.85 million, driven by a multi-year teleradiology contract expected to significantly boost its annual recurring revenue.
HC Wainwright & Co. Initiates Coverage on Rani Therapeutics Holdings with a Buy Rating and Sets Price Target at $11
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Maxim Group Reaffirms Buy Rating for Rani Therapeutics Holdings, Increases Price Target to $10
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead
Tactile Systems Technology Inc. (TCMD): The company saw a 22.13% increase in after-hours trading after reporting a strong Q3 2025 earnings with net income rising to $8.2 million and revenue climbing 17% year-over-year. They also raised their full-year revenue guidance to $317 million - $321 million.
Biodesix Inc. (BDSX): Shares surged 10.57% after the company reported a 20% increase in Q3 2025 revenue to $21.8 million and a narrowed net loss. They raised their full-year revenue forecast to $84 million - $86 million, indicating sustained growth.
Exact Sciences Corp. (EXAS): The stock rose 7.78% following a Q3 2025 earnings report showing a 20% revenue increase to $851 million and a significantly narrowed net loss. The company also raised its full-year revenue guidance to $3.220 - $3.235 billion.
Rani Therapeutics (RANI) and Grace Therapeutics Inc. (GRCE): Rani's shares increased 5.12% ahead of a presentation at ObesityWeek 2025, while Grace's stock rose 6.11% following the full exercise of common warrants tied to a previous funding round, securing additional capital for their drug candidate.
Insider Buying Update for Tuesday, October 28: RANI and KO
Rani Therapeutics Holdings Insider Purchase: Mir Imran, the CEO of Rani Therapeutics Holdings, bought 2,083,334 shares of RANI for $1.26 million, resulting in a 228.9% gain based on the current trading price.
Coca-Cola Insider Purchase: Director Max R. Levchin purchased 14,267 shares of Coca-Cola for $998,676, marking his first purchase in the past year, with Coca-Cola's stock up 0.5% on the same day.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
3 Penny Stocks to Keep an Eye On as of October 22, 2025
Penny Stocks Overview: Beyond Meat, Rani Therapeutics, and VSee Health are highlighted as top penny stocks to watch on October 22, 2025, based on their high Dollar Volume and significant stock price movements.
Beyond Meat's Growth: Beyond Meat's stock surged by 146.3% with a Dollar Volume of $7.50 billion, following its expansion into over 2,000 Walmart stores to reach more budget-conscious consumers.
Rani Therapeutics' Licensing Deal: Rani Therapeutics experienced a 27% stock increase and a Dollar Volume of $355.82 million after announcing a $1.09 billion licensing deal with Chugai Pharmaceutical and a successful private placement.
VSee Health's Telehealth Contract: VSee Health's stock rose by 93.6% with a Dollar Volume of $248.85 million, driven by a multi-year teleradiology contract expected to significantly boost its annual recurring revenue.
HC Wainwright & Co. Initiates Coverage on Rani Therapeutics Holdings with a Buy Rating and Sets Price Target at $11
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.
Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.
Maxim Group Reaffirms Buy Rating for Rani Therapeutics Holdings, Increases Price Target to $10
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
